ugichem

greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins

Affibody is a biotech company that operates in the biopharmaceutical industry. The company's main offerings include the development of next generation biotherapeutics, with a focus on treating conditions such as psoriasis, B-cell driven autoimmune diseases, and metastatic breast cancer. Affibody primarily serves the healthcare industry. It was founded in 1998 and is based in Solna, Sweden.

Nano Carrier is a biotech company using nanotechnology to improve patient Quality of Life with a focus on cancer.

The principal aims of Shardna are the identification of genetic variants to common diseases, the structural and functional characterization of apposite protein through the study of the genetic, genealogical, epidemiological, environmental and behavioural properties of specific isolated and genetically homogenous populations in the Ogliastra region of Sardinia. The results of the project will be capped by the development of diagnostics, and therapeutic and pharmacological treatment for the cure or prevention of multifactorial illnesses. The knowledge-based system which will be used in this endevour will be of particular interest to pharmaceutical and biotech businesses working to develop drugs and diagnostic tools.

7TM Pharma focuses on the discovery and development of drugs for metabolic diseases, including obesity and cardiovascular diseases. The company's main offerings include the development of novel treatments for obesity, such as a Y4 selective agonist and a peripherally acting CB1 antagonist designed to minimize central nervous system-related side effects. These products are primarily aimed at addressing the unmet needs for effective obesity therapies with fewer side effects. It was founded in 2000 and is based in Denmark.

BioPro Pharmaceutical is the first regional biotech company in Asia to develop, market leading biopharmaceutical medicines, as well as many of the world's best known biopharmaceutical products. BioPro Pharmaceutical , Inc. has infrastructure in place in all major countries in Asia to target the market of US$30 billion. BioPro's expertise is in providing creative pharmaceutical solutions to small and medium-sized US or European companies by integrating Asia's respective business strengths in addressing the pharmaceutical needs of the Asia-Pacific region. We have the knowledge and know-how of the clinical and regulatory requirements across the Asian region . We manage more than 600 professional sales representatives. We are focused on the marketing and distribution of innovative biotech cancer products in Asian markets with the most cost-effective approaches. We anticipate intense competition in this new market sector, and are working diligently to stay at the forefront of this everchanging competitive environment. BioPro obtained the exclusive rights for the core patented technology - High Throughput Mammalian Protein Expression technology to develop cost effective protein products for bioassay and reagent support and " rapid mammalian production cell development technology and downstream support team for new generations of currently well-known and future protein drugs; We have three protein therapeutics, two antibody therapeutics and two vaccines under development.